Legislative Action Center

Legislative Action Center

The Administration’s budget proposal includes cutting funding for the National Institutes of Health by nearly $6 billion, which could seriously weaken cancer research efforts.

LLS has seen firsthand how research funding fuels the discovery and approval of lifesaving cancer cures and oppose any budget that would decimate these efforts. That’s why we’re delivering a petition to ask Congress to reject any budgetary measures that would drastically reduce funding for cancer research.

Don't let your lawmaker put an end to years of lifesaving progress. While we've made strides in cancer cures over the past decades, there’s plenty of work left to do. NIH funding is a critical part of improving the lives of blood cancer patients. Please add your voice by signing the petition.

The House of Representatives passed the American Health Care Act with less than a day of debate on the latest version, and with a dangerous lack of protections for blood cancer patients and others.

The Leukemia & Lymphoma Society believes any changes to our health care laws need to provide for stable, quality, affordable care for all – because even a short gap in treatment can have disastrous consequences for blood cancer patients. This bill doesn’t include nearly enough protections for people with pre-existing conditions, like blood cancer patients and survivors, which would mean higher premiums and more barriers between patients and their treatments.

We need to thank those Representatives who stood up for cancer patients – and call out those who didn’t.

Medicare Part D is supposed to help seniors manage the cost of their prescriptions. But too many of the most vulnerable seniors on Medicare – those with life-threatening conditions like cancer, HIV/AIDS, rheumatoid arthritis, and multiple sclerosis – are facing extreme co-pays because their medication falls onto a "specialty tier."

The Part D Beneficiary Appeals Fairness Act is a promising bi-partisan bill that would allow patients a chance to appeal this "specialty tiers" designation, giving seniors battling cancer and other chronic illnesses a way to get the medications they need without going bankrupt.

Devastatingly high out-of-pocket costs can make it impossible for cancer patients to afford their treatments. The Patients' Access to Treatments Act will change that and ensure that more people can get the treatment they need. Stand with cancer patients across the country today by sending a letter to Congress!

Cancer research is critical for developing new treatments and saving more patients' lives. But accounting for inflation, federal funding has dropped 24 percent since 2003. It's up to us to bring it back - tell Congress to restore funding for cancer research!

The House of Representatives passed the American Health Care Act with less than a day of debate on the latest version, and with a dangerous lack of protections for blood cancer patients and others.
The Leukemia & Lymphoma Society believes any changes to our health care laws need to provide for stable, quality, affordable care for all – because even a short gap in treatment can have disastrous consequences for blood cancer patients. This bill doesn’t include nearly enough protections for people with pre-existing conditions, like blood cancer patients and survivors, which would mean higher premiums and more barriers between patients and their treatments.
We need to thank those Representatives who stood up for cancer patients – and call out those who didn’t.

Follow us

Sign up for latest news

This field is requiredEmail address

The Leukemia & Lymphoma Society (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.

The Leukemia & Lymphoma Society is a 501(c)(3) organization, and all monetary donations are tax deductible to the fullest extent allowed by tax laws. Please check with your financial advisor if you have more questions.